Jennifer E Towne

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi request reprint Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs
    Jennifer E Towne
    Amgen Corporation, Seattle, Washington 98101, USA
    J Biol Chem 279:13677-88. 2004
  2. pmc Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity
    Jennifer E Towne
    Department of Inflammation Research, Amgen Incorporated, Seattle, Washington 98119, USA
    J Biol Chem 286:42594-602. 2011
  3. doi request reprint IL-1RL2 and its ligands contribute to the cytokine network in psoriasis
    Hal Blumberg
    Amgen, Seattle, WA 98119, USA
    J Immunol 185:4354-62. 2010
  4. pmc Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation
    Hal Blumberg
    Department of Inflammation, 2Department of Pathology, 3Department of Biostatistics, Amgen, Seattle, WA 98119, USA
    J Exp Med 204:2603-14. 2007
  5. pmc The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings
    David A Martin
    Medical Sciences, Amgen, Seattle, WA, USA
    J Invest Dermatol 133:17-26. 2013

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs
    Jennifer E Towne
    Amgen Corporation, Seattle, Washington 98101, USA
    J Biol Chem 279:13677-88. 2004
    ..We conclude that IL-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP...
  2. pmc Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity
    Jennifer E Towne
    Department of Inflammation Research, Amgen Incorporated, Seattle, Washington 98119, USA
    J Biol Chem 286:42594-602. 2011
    ..In addition, truncation of IL-36α, IL-36β, and IL-36γ dramatically enhances their activity, suggesting that post-translational processing is required for full activity...
  3. doi request reprint IL-1RL2 and its ligands contribute to the cytokine network in psoriasis
    Hal Blumberg
    Amgen, Seattle, WA 98119, USA
    J Immunol 185:4354-62. 2010
    ..Blockade of IL-1F6 receptor also resolves the inflammatory changes in human psoriatic lesional skin transplanted onto immunodeficient mice. These data suggest a role for IL-1F family members in psoriasis...
  4. pmc Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation
    Hal Blumberg
    Department of Inflammation, 2Department of Pathology, 3Department of Biostatistics, Amgen, Seattle, WA 98119, USA
    J Exp Med 204:2603-14. 2007
    ..In summary, dysregulated expression of novel agonistic and antagonistic IL-1 family member ligands can promote cutaneous inflammation, revealing potential novel targets for the treatment of inflammatory skin disorders...
  5. pmc The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings
    David A Martin
    Medical Sciences, Amgen, Seattle, WA, USA
    J Invest Dermatol 133:17-26. 2013
    ..Therapeutic agents in development that target IL-17 are discussed, and an emerging model of the key role of IL-17 in the pathogenesis of psoriasis is presented...